Bortezomib is safe in and stabilizes pulmonary function in patients with allo-HSCT-associated pulmonary CGVHD

• Published in: Bone marrow transplantation (Basingstoke) Vol. 53; no. 9; pp. 1124 - 1130
• Main Authors: Jain, Manu, Budinger, Grs, Jovanovic, Borko, Dematte, Jane, Duffey, Sara, Mehta, Jayesh
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 01.09.2018
• Subjects: Antineoplastic agents; Bone marrow; Bortezomib; Care and treatment; Complications and side effects; Development and progression; Diagnosis; Disease control; Effectiveness; Graft vs. host disease; Graft-versus-host reaction; Hematopoietic stem cell transplantation; Lung diseases; Medical research; Medical schools; Multiple myeloma; Patient outcomes; Patients; Proteasome inhibitors; Pulmonary function tests; Pulmonary functions; Respiratory function; Safety; Stem cell transplantation; Targeted cancer therapy; Toxicity
• ISSN: 0268-3369; 1476-5365
• DOI: 10.1038/s41409-018-0134-4

Pulmonary chronic graft-versus-host disease (p-CGVHD) following allogeneic HSCT is devastating with limited proven treatments. Although sporadically associated with pulmonary toxicity, the proteasome inhibitor bortezomib may be efficacious in p-CGVHD. We sought to establish safety and tolerability of bortezomib in pilot, open-label trial of patients with p-CGVHD. The primary endpoint was adverse events. Efficacy was assessed by comparing FEV1 decline prior to p-CGVHD diagnosis to during the bortezomib treatment period. The impact on pulmonary function testing of prior long-term bortezomib treatment in multiple myeloma (MM) patients was also assessed as a safety analysis. Seventeen patients enrolled in the pilot study with a mean time to p-CGVHD diagnosis of 3.36 years (±1.88 years). Bortezomib was well tolerated without early dropouts. The median FEV1 decline prior to the diagnosis of p-CGVHD was -1.06%/month (-5.36, -0.33) and during treatment was -0.25%/month (-9.42, 3.52). In the safety study, there was no significant difference in any PFT parameter between 73 patients who received bortezomib and 68 patients who did not for MM. Thus, we conclude that bortezomib has acceptable safety and tolerability in patients with compromised pulmonary function. The efficacy of proteosomal inhibition should be assessed in a large trial of chronic p-CGVHD patients.